# Artiva Biotherapeutics, Inc. (ARTV)

> Source: Nexqual · https://nexqual.com/ARTV · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Artiva Biotherapeutics, Inc. (ARTV), nexqual.com/ARTV" · informational, not investment advice.

**Price:** USD 6.2 (-4.47% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 6.49 · day 6.16–6.65 · 52w 2.96–14.53 · market cap $303M · NGM

## Key facts
- 1 of 80 tracked superinvestors hold ARTV (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 17 Form 4 filings, $2.5M; 13 not under a Rule 10b5-1 plan ($1.9M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 10 Form 4 filings, $109M; 0 by opportunistic insiders, 0 by routine insiders.
- Total return with dividends: 1Y +28.1% vs S&P 500 +14.9%; 5Y -48.3% vs S&P 500 +80.3%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|
| Revenue | $33.5M | $251K | $0K | — |
| Operating income | -$30.7M | -$67.3M | -$89.8M | -$96.1M |
| Net income | -$28.7M | -$65.4M | -$83.9M | -$90.8M |
| EPS (diluted) | -$35.78 | -$5.81 | -$3.43 | — |
| Free cash flow | -$50.7M | -$55.7M | -$79.3M | -$76.9M |
| Operating margin | -91.6% | -26805.6% | — | — |
| Net margin | -85.8% | -26045.0% | — | — |
| Revenue growth | — | -99.3% | -100.0% | — |
| Cash + short-term investments | $77.0M | $185M | $108M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 0.9x · FCF yield -25.37% · Earnings yield -29.96%

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold ARTV. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 0.07% | $25.3M | New position |

## Insider sales (SEC Form 4, open-market, last ~7 months)
4 of 17 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-06 | Aslan Fred | Chief Executive Officer | 23,463 | $169K | 1.5% | Yes (adopted May 13, 2026) | Too little history (no open-market trades in 2023 or 2024) |
| 2026-10-05 | Horan Christopher | Chief Tech Operations Officer | 10,340 | $71K | 3.2% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-10-05 | Bush Jennifer | COO, CLO, Compliance Officer | 8,370 | $57K | 2.2% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-10-05 | Banerjee Subhashis | Chief Medical Officer | 1,099 | $8K | 0.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-10-05 | Aslan Fred | Chief Executive Officer | 61,696 | $422K | 3.8% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-09-08 | Aslan Fred | Chief Executive Officer | 23,429 | $256K | 1.6% | Yes (adopted May 13, 2026) | Too little history (no open-market trades in 2023 or 2024) |
| 2026-09-03 | Horan Christopher | Chief Tech Operations Officer | 10,366 | $116K | 3.5% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-09-03 | Bush Jennifer | COO, CLO, Compliance Officer | 8,391 | $94K | 2.5% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-09-03 | Banerjee Subhashis | Chief Medical Officer | 1,100 | $12K | 0.8% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-09-03 | Aslan Fred | Chief Executive Officer | 61,888 | $690K | 4% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-08-27 | Banerjee Subhashis | Chief Medical Officer | 8,222 | $99K | 5.5% | Yes (adopted May 14, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-08-18 | Banerjee Subhashis | Chief Medical Officer | 429 | $5K | 0.3% | Yes (adopted May 14, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-05-19 | Raymon Heather | SVP, Research and Development | 3,095 | $28K | 2% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-19 | Horan Christopher | Chief Tech Operations Officer | 7,002 | $63K | 2.3% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-19 | Bush Jennifer | COO, CLO, Compliance Officer | 8,790 | $79K | 2.5% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-19 | Banerjee Subhashis | Chief Medical Officer | 7,037 | $63K | 4.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-19 | Aslan Fred | Chief Executive Officer | 27,116 | $244K | 1.7% | No | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Insider purchases (SEC Form 4, open-market, last ~7 months)
10 purchases, $109M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-07-29…2026-07-31 | Ra Capital Management, L.P. | Director | 45,768 | $456K | 9.96 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-07-24 | Ra Capital Management, L.P. | Director | 41,319 | $413K | 9.99 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-07-21…2026-07-23 | Ra Capital Management, L.P. | Director | 264,586 | $2.6M | 9.76 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-07-16…2026-07-17 | Ra Capital Management, L.P. | Director | 160,354 | $1.4M | 8.93 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-07-10…2026-07-13 | Ra Capital Management, L.P. | Director | 21,654 | $194K | 8.96 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-06-25…2026-06-26 | Ra Capital Management, L.P. | Director | 32,876 | $292K | 8.89 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-06-12…2026-06-16 | Ra Capital Management, L.P. | Director | 531,326 | $4.6M | 8.66 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-06-09…2026-06-11 | Ra Capital Management, L.P. | Director | 1,027,722 | $7.7M | 7.44 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-05-11 | Gc Corp. |  | 1,432,291 | $16.5M | 11.52 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-05-11 | Ra Capital Management, L.P. | Director | 6,510,416 | $75.0M | 11.52 | Too little history (no open-market trades in 2023 or 2025) |

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-02 | Cantor Fitzgerald | Reiterated | Overweight | $40 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2024-07-15) |
|---|---|---|
| Total return | +28.1% | -48.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +28.2% | -25.2% |
| Volatility (annualized) | 121.6% | 123.3% |
| Max drawdown | -56.3% (Apr 2026→Oct 2026) | -90.7% (Sep 2024→Jun 2025) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 307.82 -2.21% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 90.9 +2.57% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.14 -3.28% · PRAX (Praxis Precision Medicines, Inc) USD 258.92 +0.96% · IONS (Ionis Pharmaceuticals, Inc.) USD 43.91 -0.81% · ABVX (Abivax SA) USD 90.23 -3.49%

## More
Full page: https://nexqual.com/ARTV · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.53 | $-0.52 | +2.2% | $0 | 5 |
| Next quarter (ends 2026-12-31) | $-0.58 | $-0.56 | +2.9% | $0 | 5 |
| Current fiscal year (ends 2026-12-31) | $-2.51 | $-2.43 | +3.2% | $0 | 5 |
| Next fiscal year (ends 2027-12-31) | $-2.61 | $-2.81 | -7.4% | $0 | 5 |